Synchron Raises US$200 Million in Series D Financing
Synchron has secured US$200 million in a Series D financing round to accelerate the commercialization of its first-generation Stentrode brain-computer interface (BCI) platform. The funding will also support the advancement of a “next-generation, transcatheter, high-channel whole-brain interface.”
Funding Objectives and Developments
With this investment, Synchron plans to expedite pivotal trials and prepare for the commercial launch of the Stentrode BCI system. The company aims to expand its team by hiring engineers, neuroscientists, and operators to further develop the latest generation of BCIs.
Investors and Financial Impact
- The financing round was led by Double Point Ventures.
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New investors joining the round are the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
The company stated that the Series D funding will bolster efforts to advance the next generation of BCIs through continued hiring and research.
This recent funding brings Synchron’s total capital raised to US$345 million, enabling it to push forward its innovative brain-computer interface technologies.
Author's summary: Synchron’s US$200 million Series D round boosts the commercialization and development of cutting-edge brain-computer interfaces, reflecting strong investor confidence and ambition in neurotechnology.